focus -WSS

focus

author：Wikipedia 2025-09-29 22:48:14 - browse：274

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： At least 13 dead in Texas as scorching temps continue

entertainment

WSS

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Change Healthcare outage fallout shows need for new oversight

Steward Health Care Massachusetts hospitals face fiscal disaster

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

UCLA team creates talking throat patch for voice disorders

hotspot

focus

entertainment

Jerome Adams on the need for new antivirals for Covid

EPA limits use of carcinogenic gas for sterilizing medical devices

Jerome Adams on the need for new antivirals for Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

State Dept. review finds Biden bears some blame for Afghanistan failures

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

DIEP, the 'gold standard' of breast reconstruction, is under threat

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Change Healthcare outage fallout shows need for new oversight

Wikipedia

Change Healthcare outage fallout shows need for new oversight

Continuity nursing helped my family in our darkest PICU moments

Affirmative action in medical school literally saved lives

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

DIEP, the 'gold standard' of breast reconstruction, is under threat

After affirmative action ruling, medical educators look to 'holistic review'

Wikipedia

entertainment

explore

focus